Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Association between baseline fetal hemoglobin levels and incidence of severe vaso-occlusive pain episodes in children with sickle cell anemia.

Bhatnagar P, Keefer JR, Casella JF, Barron-Casella EA, Bean CJ, Hooper CW, Payne AB, Arking DE, Debaun MR.

Pediatr Blood Cancer. 2013 Oct;60(10):E125-7. doi: 10.1002/pbc.24588. Epub 2013 May 15.

2.

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.

JAMA. 2003 Apr 2;289(13):1645-51. Erratum in: JAMA. 2003 Aug 13;290(6):756.

PMID:
12672732
3.

A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.

Estepp JH, Smeltzer MP, Kang G, Li C, Wang WC, Abrams C, Aygun B, Ware RE, Nottage K, Hankins JS.

Am J Hematol. 2017 Dec;92(12):1333-1339. doi: 10.1002/ajh.24906. Epub 2017 Sep 28.

PMID:
28913922
4.

Hemorheological risk factors of acute chest syndrome and painful vaso-occlusive crisis in children with sickle cell disease.

Lamarre Y, Romana M, Waltz X, Lalanne-Mistrih ML, Tressières B, Divialle-Doumdo L, Hardy-Dessources MD, Vent-Schmidt J, Petras M, Broquere C, Maillard F, Tarer V, Etienne-Julan M, Connes P.

Haematologica. 2012 Nov;97(11):1641-7. doi: 10.3324/haematol.2012.066670. Epub 2012 Jun 11.

5.

Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia.

Darbari DS, Onyekwere O, Nouraie M, Minniti CP, Luchtman-Jones L, Rana S, Sable C, Ensing G, Dham N, Campbell A, Arteta M, Gladwin MT, Castro O, Taylor JG 6th, Kato GJ, Gordeuk V.

J Pediatr. 2012 Feb;160(2):286-90. doi: 10.1016/j.jpeds.2011.07.018. Epub 2011 Sep 3.

6.
7.

The relationship between fetal hemoglobin and disease severity in children with sickle cell anemia.

Odenheimer DJ, Sarnaik SA, Whitten CF, Rucknagel DL, Sing CF.

Am J Med Genet. 1987 Jul;27(3):525-35.

8.

Absolute Reticulocyte Count Acts as a Surrogate for Fetal Hemoglobin in Infants and Children with Sickle Cell Anemia.

Meier ER, Byrnes C, Weissman M, Lee YT, Miller JL.

PLoS One. 2015 Sep 14;10(9):e0136672. doi: 10.1371/journal.pone.0136672. eCollection 2015.

9.

Hydroxyurea therapy in children severely affected with sickle cell disease.

Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.

J Pediatr. 1996 Jun;128(6):820-8.

PMID:
8648542
10.

Level of fetal hemoglobin as an indicator of clinical complications in sickle cell anemia.

Bordin JO, Kerbauy J, Lourenço DM, Sesso R.

Braz J Med Biol Res. 1989;22(11):1347-53.

PMID:
2484125
11.

Pain in sickle cell disease. Rates and risk factors.

Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR.

N Engl J Med. 1991 Jul 4;325(1):11-6.

12.

Modulation of pain in pediatric sickle cell disease: understanding the balance between endothelin mediated vasoconstriction and apelin mediated vasodilation.

Smith TP, Schlenz AM, Schatz JC, Maitra R, Sweitzer SM.

Blood Cells Mol Dis. 2015 Feb;54(2):155-9. doi: 10.1016/j.bcmd.2014.11.016. Epub 2014 Nov 26.

13.

The effect of increased fetal hemoglobin production on the frequency of vaso-occlusive crisis in sickle cell disease.

Dover GJ, Charache S.

Prog Clin Biol Res. 1987;240:277-85. No abstract available.

PMID:
2441416
14.

Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.

Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K.

Blood. 2002 Jan 1;99(1):10-4.

15.

Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.

Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A.

Hemoglobin. 2012;36(4):323-32. doi: 10.3109/03630269.2012.697948.

PMID:
22734586
16.

Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.

Maier-Redelsperger M, de Montalembert M, Flahault A, Neonato MG, Ducrocq R, Masson MP, Girot R, Elion J.

Blood. 1998 Jun 15;91(12):4472-9.

17.

Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.

Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP.

Pediatrics. 2003 Jun;111(6 Pt 1):e661-5.

PMID:
12777582
18.

Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia.

Miller ST, Wright E, Abboud M, Berman B, Files B, Scher CD, Styles L, Adams RJ; STOP Investigators.

J Pediatr. 2001 Dec;139(6):785-9.

PMID:
11743502
19.

Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.

Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.

Blood Cells Mol Dis. 2009 Jan-Feb;42(1):25-31. doi: 10.1016/j.bcmd.2008.08.003. Epub 2008 Oct 26.

PMID:
18954999
20.

Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.

Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, Visintainer P.

J Pediatr. 1996 Oct;129(4):559-65.

PMID:
8859263

Supplemental Content

Support Center